Sam Donaldson to chair philanthropic arm of the National Comprehensive Cancer Network
The NCCN 15th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care got underway this past week by naming longtime ABC news anchor (and cancer survivor) Sam Donaldson to the Chair of the Board of Directors for the newly established NCCN Foundation.
The NCCN Foundation will function as the philanthropic arm of the National Comprehensive Cancer Network. Among the primary initiatives of the Foundation is gaining "support for the development of the NCCN Patient Guidelines." Currently the NCCN publishes the highly influential Clinical Practice Guidelines in Oncology, which provides cancer treatment guidelines to oncologists. The Foundation will be actively working to create "translations" of those guidelines into text that patients and caregivers can easily understand.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
